Jo Shorthouse

London

Writer at Freelance

Featured in: Favicon

informa.com (+3) Favicon

medicaldevice-network.com Favicon

chemistanddruggist.co.uk Favicon

citeline.com Favicon

invivo.citeline.com

Articles

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

1 week ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic RenaissanceRob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.
UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

1 week ago | insights.citeline.com | Jo Shorthouse
Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

3 weeks ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
‘I Want Everything To Go Faster’: Medidata’s CEO On Pushing The Strategic Accelerator

4 weeks ago | insights.citeline.com | Jo Shorthouse

‘I Want Everything To Go Faster’: Medidata’s CEO On Pushing The Strategic Accelerator Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries. Anthony Costello Presents At Medidata's NEXT Conference (Medidata)
Merck KGaA’s Digital Biomarker Strategy For Commercial Gains In Neurology

1 month ago | insights.citeline.com | Jo Shorthouse

Merck KGaA’s Digital Biomarker Strategy For Commercial Gains In Neurology The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.
Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

1 month ago | insights.citeline.com | Jo Shorthouse

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision TherapiesIn Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.
Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

1 month ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
In Vivo’s 2025 Rising Leaders

1 month ago | insights.citeline.com | Jo Shorthouse

In Vivo’s 2025 Rising Leaders30 Rising Leaders Across The Life Sciences SectorThe sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
In Vivo’s 2025 Rising Leaders At A Glance

1 month ago | insights.citeline.com | Jo Shorthouse

In Vivo’s 2025 Rising Leaders At A Glance Top 30 leaders: see the list of industry influencers highlighted in the six edition of In Vivo's Rising Leaders series.
Antag Therapeutics: Developing Peptide-Based Treatments For Obesity Management

1 month ago | insights.citeline.com | Jo Shorthouse

Antag Therapeutics: Developing Peptide-Based Treatments For Obesity ManagementAntag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.